MYSTERIOUS: Medical devices - You Need To See This

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

Despite Abbott’s recent underperformance over the past year, Wall Street analysts remain optimistic about the stock’s prospects.

The stock market will likely stay under pressure this year, with stubborn inflation and elevated interest rates. However, the Fed’s decision could largely be influenced by concerns about the recent banking crisis. Amid such uncertainty, fundamentally sound stocks Johnson & Johnson (JNJ), Abbott Laboratories (ABT), and Humana (HUM) could be…

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…

Worries over intensifying supply disruptions with growing sanctions on Russia have shaken investors. Furthermore, rising crude oil prices coupled with record-high inflation have given rise to recession fears. Thus, we think it could be wise to bet on ultra-safe dividend aristocrats Johnson & Johnson (JNJ), Walmart (WMT), PepsiCo (PEP), Abbott…

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…